Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSMITTER Substudy: Accuracy of IEM Detection by MIND1
NCT02091882Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Percentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection at Day 1. Started Mar 2014; status: completed.
Beyond the preview
Go deeper on NCT02091882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091882.